1. Home
  2. AKTX vs TGE Comparison

AKTX vs TGE Comparison

Compare AKTX & TGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

SELL

Current Price

$7.18

Market Cap

15.4M

Sector

Health Care

ML Signal

SELL

TGE

The Generation Essentials Group Class A Ordinary Shares

HOLD

Current Price

$0.19

Market Cap

12.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKTX
TGE
Founded
N/A
2023
Country
United States
France
Employees
N/A
166
Industry
Biotechnology: Pharmaceutical Preparations
Newspapers/Magazines
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
12.6M
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
AKTX
TGE
Price
$7.18
$0.19
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
★ $25.50
N/A
AVG Volume (30 Days)
32.2K
★ 880.8K
Earning Date
11-12-2026
09-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
$2.99
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.18
52 Week High
$29.32
$1.69

Technical Indicators

Market Signals
Indicator
AKTX
TGE
Relative Strength Index (RSI) 42.25 24.12
Support Level $5.01 N/A
Resistance Level $9.91 $0.99
Average True Range (ATR) 0.90 0.08
MACD -0.06 0.00
Stochastic Oscillator 24.25 8.06

Price Performance

Historical Comparison
AKTX
TGE

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About TGE The Generation Essentials Group Class A Ordinary Shares

The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.

Share on Social Networks: